Electrameccanica Vehicles Corp. SOLO 深 滬
等待開盤 12-20 09:30:00 美东时间
0.2122
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.2122
- 總市值 2525.18万
- 52周最高 1.04
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.1999
- 委 比 0.00%
- 總股本 1.19亿
- 歷史最高 13.60
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.1999
- 每 手 1
- 風險率 0.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Solo Brands To Merge Solo Stove Holdings Into Wholly Owned Subsidiary, Simplifying Corporate Structure And Retiring Class B Shares
On December 17, 2025, Solo Brands, Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Solo Stove Holdings, LLC ("Holdings") and Solo Merger Sub LLC ("Merger Sub"), a
12-18 05:42
Xanadu to receive up to $23M from new Canadian Quantum Champions Program
Xanadu Quantum Technologies Inc. has been selected to participate in Canada's Quantum Champions Program (CQCP), a federal initiative to advance fault-tolerant quantum computing. The company will receive up to CAD $23 million in funding to develop practical quantum solutions across industries. Xanadu’s photonic quantum architecture offers advantages like room-temperature operations and modular design, showcased by its Aurora platform. The initiati...
12-15 15:00
'Boring' ETF Is Winning Big As Investors Park Billions During Murky Fed Outlook
SGOV emerges as the week's unlikely standout, pulling in billions. Here's why this "boring" ultra-short Treasury ETF is suddenly in demand.
12-10 02:56
ServiceNow Makes Major AI Play To Modernize Canada's Public Sector
ServiceNow Inc. (NYSE: NOW) pledges $110 million for AI adoption in Canada, including 100 new jobs and a local data center.
12-08 22:04
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
BiomX Inc. has halted its Phase 2b clinical trial of BX004, a nebulized phage therapy for cystic fibrosis patients with chronic *Pseudomonas aeruginosa* infections, following high adverse event rates and recommendations from the Data Monitoring Committee. The company is implementing cost-cutting measures, including workforce reduction, while evaluating strategic alternatives. BiomX remains committed to advancing BX011, its fixed phage cocktail ta...
12-08 12:30
Conico Limited Announces Director Change
An announcement from Conico Limited ( ($AU:CNJ) ) is now available. Conico Limi...
12-04 16:47
金银铜45年来首次“三箭齐发”同创新高，涨势未完待续！
强劲的牛市让金银铜在2025年收获巨大涨幅。但令交易员尤为关注的是，这是自1980年来三大金属首次在同一年度全部刷新最高纪录。与45年前相比，驱动本轮涨势的因素已发生深刻变化。
12-03 23:00
Angel Accelerates DAVID Theatrical Rollout Across 43 International Markets
Animated musical builds powerful momentum as early domestic pre-sales surge close to $6 million PROVO, Utah, Nov. 26, 2025 /PRNewswire/ -- Angel (NYSE: ANGX), a media and technology company ...
11-26 23:32
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
BiomX is addressing FDA follow-up requests regarding the nebulizer device used in its Phase 2b trial for BX004, targeting *P. aeruginosa* in cystic fibrosis patients. An independent DMC completed a safety review, recommending continued study with revised dosing. The trial protocol is being updated, and top-line results are now expected in Q2 2026. Enrollment in the U.S. will resume once FDA requests are resolved.
11-25 21:40
